Anti-inflammatory and metabolic effects of candesartan in hypertensive patients
Anti-inflammatory and metabolic effects of candesartan in hypertensive patients
复制标题
DOI：
10.1016/j.ijcard.2005.07.040
复制
发表时间：
2006-03-22
影响因子：
3.5
通讯作者：
Shin, EK
中科院分区：
文献类型：
--
作者：
Koh, KK;Quon, MJ;Shin, EK
背景：血管紧张素II型1 （ATI）受体阻滞剂治疗可预防或延缓冠心病的进展。这种益处的机制可能与ATI受体阻滞剂减少炎症和胰岛素抵抗的能力有关。方法：我们给45例轻中度高血压患者服用安慰剂或坎地沙坦16 mg，持续2个月。本研究采用随机、双盲、安慰剂对照、交叉设计。结果：坎地沙坦治疗可显著降低收缩压和舒张压。与安慰剂相比，坎地沙坦治疗显著降低血浆hsCRP水平（相对于基线测量值），从1.10降至0.70 mg/l (P=0.024)，可溶性CD40配体水平降低30 +/- 11% （P < 0.001）。体重指数与基线血浆脂联素水平呈显著负相关（r = -0.480, P = 0.009）。基线脂联素水平与基线胰岛素（r = -0.317, P = 0.034）或基线胰岛素敏感性替代指标定量胰岛素敏感性检查指数（QUICKI）有显著相关性（r = 0.371, P = 0.012）。与安慰剂相比，坎地沙坦治疗显著降低空腹胰岛素水平（P = 0.011），血浆脂联素水平升高15 +/- 4% (P = 0.012)， QUICKI升高8 +/- 2% （P = 0.007）。脂联素水平变化百分比与胰岛素变化百分比（r = -0.340, P = 0.022）或QUICKI变化百分比（r = 0.325, P = 0.029）之间存在显著相关性。结论：坎地沙坦治疗可显著降低高血压患者的炎症，增加脂联素水平，改善胰岛素敏感性。(c) 2005爱思唯尔爱尔兰有限公司版权所有。
Background: Angiotensin II type 1 (ATI) receptor blocker therapy prevented or retarded the progression of coronary heart disease. The mechanisms of this benefit may relate to the ability of ATI receptor blockers to reduce inflammation and insulin resistance.Methods: We administered placebo or candesartan 16 mg daily during 2 months to 45 patients with mild to moderate hypertension. This study was randomized, double-blind, placebo-controlled, crossover in design.Results: Candesartan therapy significantly lowered both systolic and diastolic blood pressure. Compared with placebo, candesartan therapy significantly lowered plasma hsCRP levels relative to baseline measurements from 1.10 to 0.70 mg/l (P=0.024) and soluble CD40 ligand levels by 30 +/- 11% (P < 0.001). There were significant inverse correlations between body mass index and baseline plasma adiponectin levels (r = -0.480, P = 0.009). There were significant correlations between baseline adiponectin levels and baseline insulin (r = -0.317, P = 0.034) or baseline Quantitative Insulin-Sensitivity Check Index (QUICKI), a surrogate index of insulin sensitivity (r = 0.371, P = 0.012). Compared with placebo, candesartan therapy significantly lowered fasting insulin levels (P = 0.011) and increased plasma levels of adiponectin by 15 +/- 4% (P = 0.012) and increased QUICKI by 8 +/- 2% (P = 0.007). There were significant correlations between percent changes in adiponectin levels and percent changes in insulin (r = -0.340, P = 0.022) or QUICKI (r = 0.325, P = 0.029).Conclusions: Candesartan therapy significantly reduced inflammation and increased adiponectin levels and improved insulin sensitivity in hypertensive patients. (c) 1 2005 Elsevier Ireland Ltd. All rights reserved.